Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma

A multicenter, randomized, double-blind, phase II clinical study designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of Becotatug Vedotin for Injection in combination with PD-1 in patients with locally advanced resectable head and neck squamous cell carcinoma

Trial Details

NCT ID
NCT07586124
Phase
PHASE2
Sponsor
Lepu Biopharma Co., Ltd.
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Becotatug Vedotin for Injection
  • Placebo
  • Pucotenlimab Injection
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Shantou, Guangdong, China|23.35489,116.67876

Key Eligibility Criteria

  • Life expectancy ≥ 6 months.
  • Subjects with histologically confirmed, resectable Stage III-IVA head and neck squamous cell carcinoma (HNSCC) eligible for curative-intent surgery.
  • At least one extracranial measurable lesion per RECIST v1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →